Sign in
Not yet taking people in United StatesPhase 2

Tests NA-931 with or without tirzepatide in adults with obesity or overweight

Tests a pill, NA-931, alone or with tirzepatide in adults who have obesity or overweight.

Key facts

Who runs it
Biomed Industries, Inc.
Where
Hialeah, Jacksonville, Lake Worth, Los Angeles, New York, San Diego, San Francisco, and Sugar Land, United StatesSee the 8 sitesAlso in 2 other countries, 9 sites
Trial code
Registry title
Safety and Efficacy of NA-931 and Tirzepatide in Adults Who Are Overweight or Obese
Status
Not yet recruiting
Phase
Phase 2
People taking part
224 people, planned
Started
15 Aug 2026
Expected to end
15 Dec 2027
Type of study
Interventional, 9 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • NA-931
  • Tirzepatide
  • NA-931 150 mg + no Tirzepatide
Record updated
27 March 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with overweight or obesity who have tried to lose weight on their own without success.

Age
18 to 80 years (the registry header lists 19 to 80 years)
Sex
Men and women can join.
Disease stage
BMI of 30 or more, or BMI of 27 or more with one or more weight-related health problems such as high blood pressure, insulin resistance, sleep apnea or high blood fats. Body weight under 150 kg (331 lb).
Earlier treatment
At least one self-reported unsuccessful effort to lose weight through behaviour change. No medication for obesity in the 30 days before screening.

Main reasons for not taking part

  • Known allergy to monoclonal antibody drugs or a reason not to take Tirzepatide
  • Diabetes treated with diabetes drugs, or HbA1c of 6.5% (48 mmol/mol) or more
  • Chronic infection such as hepatitis B, hepatitis C or HIV, or active COVID-19
  • Other investigational drugs within 30 days or 5 half-lives
  • Weight change of more than 5 kg (11 lb) in the 90 days before screening

The registry criteria, word for word

Show all 7 criteriaShow less

Who can take part

  • A written informed consent must be obtained before any study-related assessments are performed
  • Men and women between 18 and 80 years, inclusive; women of child-bearing potential (defined as those who are not post-menopausal or post-surgical sterilization) must meet both of the following criteria:; Two negative pregnancy tests (at screening and at randomization, prior to dosing); Use of intrauterine device, from at least 3 months before the baseline visit through at least 4 months after the last dose of NA-931/placebo oral, and an additional contraceptive (barrier) method from screening through at least 4 months after the last dose of NA-931/placebo oral
  • Body mass index (BMI) ≥ 30 or BMI ≥ 27 with one or more obesity-associated comorbidities (e.g., hypertension, insulin resistance, sleep apnea, or dyslipidemia)
  • Stable body weight (± 5 kg) within 90 days of screening, and body weight <150 kg
  • Have a history of at least one self-reported unsuccessful behavioral effort to lose body weight
  • Able to communicate well with the Investigator, comply with the study requirements and adhere to the diet and activity programs for the study duration

Who cannot take part

  • • History of, or known hypersensitivity to, monoclonal antibody drugs or a contraindication to Tirzepatide (Zepbound® or Mounjaro®); Use of other investigational drugs at the time of enrollment or within 30 days or 5 half-lives of enrollment, whichever is longer, or longer if required by local regulations; Treatment with any medication for the indication of obesity within the past 30 days before screening; Diagnosis of diabetes requiring current use of any antidiabetic drug or HbA1c ≥ 6.5% Note: Metabolic syndrome is not an exclusion, even if managed with an anti-diabetic drug such as metformin or an SGLT2 inhibitor. A diagnosis of prediabetes or impaired glucose tolerance managed exclusively with non-pharmacologic approaches (e.g., diet and exercise) is not an exclusion; Any chronic infections likely to interfere with study conduct or interpretation such as hepatitis B (HBV), hepatitis C (HCV), or human immunodeficiency virus (HIV). History of hepatitis A or hepatitis C successfully treated is not exclusionary. Active COVID-19 infection; Donation or loss of 400 mL or more of blood within 8 weeks prior to initial dosing, or longer if required by local regulation, or plasma donation (> 250 mL) within 14 days prior to the first dose; Any disorder, unwillingness, or inability not covered by any of the other exclusion criteria, which in the Investigator's opinion, might jeopardize the participant's safety or compliance with the protocol

Check if you might fit

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 19 and 80 years old?

Where in United States

Also in 2 other countries, 9 sites

  • Biomed Research Unit # 33012-104Hialeah, United StatesContact: David Nguyen, PhDNot yet recruiting
  • Biomed Research Unit # 32256-105Jacksonville, United StatesContact: David Nguyen, PhDNot yet recruiting
  • Biomed Research Unit # 33461-106Lake Worth, United StatesContact: David Nguyen, PhDNot yet recruiting
  • Biomed Research Unit #90067-102Los Angeles, United StatesContact: David Nguyen, PhDNot yet recruiting
  • Biomed Research Unit # 10021-107New York, United StatesContact: David Nguyen, PhDNot yet recruiting
  • Biomed Research Unit # 92121-103San Diego, United StatesContact: David Nguyen, PhDNot yet recruiting
  • Biomed Research Unit # 94104-101San Francisco, United StatesContact: David Nguyen, PhDNot yet recruiting
  • Biomed Research Unit # 77479-108Sugar Land, United StatesContact: David Nguyen, PhDNot yet recruiting

About the trial

What the trial wants to find out

A phase 2 study to assess the efficacy of NA-931 alone or in addition to Tirzepatide to assess efficacy and safety in overweight or obese men and women

The 9 groups in the trial

  • Placebo Comparator: PlaceboPlacebo, for comparison

    Placebo Comparator: Placebo to oral NA-931 120 mg daily + no Tirzepatide Participants will receive oral placebo at baseline and at Weeks 4, 12, and 24, 36, and 48 during the core treatment period and will switch during the extension period to receive NA-931 60 mg daily at Weeks 60 and 72.

    Treatment: NA-931

  • Placebo + Tirzepatide 5 mgPlacebo, for comparison

    Other: Placebo + Tirzepatide 5 mg Participants will receive oral placebo at baseline and at Weeks 4, 12, and 24, 36, and 48, and s.c. Tirzepatide 5 mg weekly per the dose escalation schedule.

    Treatment: NA-931

  • Placebo + Tirzepatide 10 mgPlacebo, for comparison

    Placebo + Tirzepatide 10 mg Participants will receive oral placebo at baseline and at Weeks 4, 12, and 24, 36, and 48 and s.c. Tirzepatide 10 mg weekly per the dose escalation schedule.

    Treatment: Tirzepatide and NA-931 150 mg + no Tirzepatide

  • NA-931 60mg to NA-931 150 mg + no TirzepatideTreatment being tested

    Experimental: NA-931 60mg to NA-931 150 mg + no Tirzepatide Participants will receive oral NA-931 60 mg at baseline and at Weeks 4, 12, and 24, 36, and 48 during the core treatment period and will switch during the extension period to receive NA-931 60 mg at Weeks 60 and 72.

    Treatment: NA-931

  • NA-931 60 mg + Tirzepatide 5 mgExisting treatment, for comparison

    NA-931 60 mg + Tirzepatide 5 mg Participants will receive oral NA-931 60 mg at baseline and at Weeks 4, 12, and 24, 36, and 48 and s.c. Tirzepatide 5 mg weekly per the dose escalation schedule.

    Treatment: NA-931

  • NA-931 120 mg + Tirzepatide 5 mgExisting treatment, for comparison

    NA-931 120 mg + Tirzepatide 5 mg Participants will receive oral NA-931 60 mg at baseline and at Weeks 4, 12, and 24, 36, and 48 and s.c. Tirzepatide 5 mg weekly per the dose escalation schedule.

    Treatment: NA-931

  • NA-931 150 mg + no TirzepatideTreatment being tested

    Experimental: NA-931 150 mg + no Tirzepatide Participants will receive oral NA-931 150 mg at baseline and at Weeks 4, 12, 24, 36 and 48

    Treatment: Tirzepatide and NA-931 150 mg + no Tirzepatide

  • NA-931 150 mg + Tirzepatide 2.5 mgExisting treatment, for comparison

    NA-931 150 mg + Tirzepatide 2.5 mg Participants will receive oral NA-931 150 mg at baseline, and at Weeks 4, 12, and 24, 36, and 48 and s.c. Tirzepatide 2.5 mg weekly per the dose escalation schedule.

    Treatment: Tirzepatide and NA-931

  • NA-931 150 mg + Tirzepatide 5 mgExisting treatment, for comparison

    NA-931 150 mg + Tirzepatide 5 mg Participants will receive oral NA-931 150mg at baseline and at Weeks 4, 12, and 24, 36, and 48 and s.c. Tirzepatide 5 mg per the dose escalation schedule.

    Treatment: NA-931

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Randomized, Double-Blind, Placebo-Controlled Multi-Center Study of Oral NA-931, Alone or in Addition to Open Label Subcutaneous Tirzepatide , to Investigate the Efficacy and Safety in Overweight or Obese Men and Women
Plain-language title
Tests NA-931 with or without tirzepatide in adults with obesity or overweightGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Fit questions
Built from NCT06732245, who can take part
Record updated
27 March 2026